Psychiatry Research
Volume 144, Issue 2 , Pages 99-108 , 15 November 2006

Polymorphism in the serotonin transporter gene and moderators of prolactin response to meta-chlorophenylpiperazine in African-American cocaine abusers and controls

  • Paolo Mannelli

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    • ,
  • Ashwin A. Patkar

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    • Corresponding Author InformationCorresponding author. Duke University Medical Center, 4323 Ben Franklin Boulevard, Suite 700, Durham, NC 27704, USA. Tel.: +1 919 471 3826; fax: +1 919 620 0346.
    • ,
  • Kathleen Peindl

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    • ,
  • Haresh Tharwani

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    • ,
  • Raman Gopalakrishnan

      Affiliations

    • Department of Psychiatry, Thomas Jefferson University, Philadelphia, PA, USA
    • ,
  • Kevin P. Hill

      Affiliations

    • Department of Psychiatry, Yale University, New Haven, CT, USA
    • ,
  • Wade H. Berrettini

      Affiliations

    • Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

Received 16 October 2005 ,Revised 6 January 2006 ,Accepted 15 January 2006.

References 

  1. Aulakh S, Hill J, Murphy D. Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats. Journal of Pharmacology and Experimental Therapeutics. 1992;263:588–595
  2. Arango C, Breier A, McMahon R, Carpenter W, Buchanan R. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. American Journal of Psychiatry. 2003;160:1421–1427
  3. Arango V, Huang Y, Underwood M, Mann J. Genetics of the serotonergic system in suicidal behavior. Journal of Psychiatric Research. 2003;37:375–386
  4. Badaway A. Alcohol and violence and the possible role of serotonin. Criminal Behavior and Mental Health. 2003;13:31–44
  5. Barratt E. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychological Reports. 1965;16:547–554
  6. Beck A, Steer R. Beck Depression Inventory. The Psychological Corporation. San Antonio, TX: Harcourt, Brace, and Jovanovich; 1987;
  7. Bourson A, Wanner D, Wyler R, Petit N, Zwingelstein C, Rudler A, et al. Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine. Pharmacology, Biochemistry, and Behaviour. 1996;53:107–114
  8. Broocks A, Briggs NC, Pigott T, Hill J, Canter S, Tolliver T, et al. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. Psychopharmacology. 1997;130:91–103
  9. Broocks A, Little J, Martin A, Minichiello M, Dubbert B, Mack C, et al. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls. Biological Psychiatry. 1998;43:408–416
  10. Broocks A, Meyer T, Gleiter C, Hillmer-Vogel U, George A, Bartmann U, et al. Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects. Psychopharmacology. 2001;155:234–241
  11. Buss A, Durkee A. An inventory for assessing different kinds of hostility. Journal of Consulting Psychology. 1957;21:343–348
  12. Buydens-Branchey L, Branchey M, Gribomont B, Handelsman L, Holloway K, Silverman J. Morbidity risk for alcoholism and drug abuse in relatives of cocaine addicts. American Journal of Drug and Alcohol Abuse. 1993;19:347–357
  13. Buydens-Branchey L, Branchey M, Fergeson P, Hudson J, McKernin C. The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses. Biological Psychiatry. 1997;41:1071–1086
  14. Buydens-Branchey L, Branchey M, Hudson J, Fergeson P. Low HDL cholesterol, aggression, and altered central serotonergic activity. Psychiatry Research. 2000;93:93–102
  15. Calogero A, Bagdy G, Moncada M, D'Agata R. Effect of selective serotonin agonists on basal, corticotrophin-releasing hormone- and vasopressin-induced ACTH release in vitro from rat pituitary cells. Journal of Endocrinology. 1993;136:381–387
  16. Coccaro E, Berman M, Kavoussi R, Hauger R. Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessments of aggression in personality disordered men. Biological Psychiatry. 1996;40:157–164(Aug)
  17. Cunningham J, Breslin F. Only one in three people with alcohol abuse or dependence ever seek treatment. Addictive Behaviors. 2004;29:221–223
  18. David S, Murthy N, Rabiner E, Muñafo M, Johnstone E, Jacob R, et al. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1a receptor binding in humans. Journal of Neuroscience. 2005;25:2586–2590
  19. Edenberg H, Foroud T, Koller D, Goate A, Rice J, Van Eerdewegh P, et al. A family-based analysis of the association of the dopamine D2 receptor (DRD2) with alcoholism. Alcohol, Clinical and Experimental Research. 1998;2:505–512
  20. Edenberg H, Reynonlds J, Koller D, Begleiter H, Bucholz K, Conneally P, et al. A family-based analysis of whether the functional promoter alleles of the serotonin transporter gene HTT affect the risk for alcohol dependence. Alcohol, Clinical and Experimental Research. 1998;5:1080–1085
  21. Feinn R, Nellisery M, Kranzler H. Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol. American Journal of Medical Genetics. 2005;133:79–84
  22. First M, Gibbon M, Spitzer R, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-IV): Clinician Version. Washington, DC: American Psychiatric Press; 1997;
  23. Frankel P, Cunningham K. M-Chlorophenylpiperazine (mCPP) modulates the discriminative stimulus effects of cocaine through actions at the 5-HT2C receptor. Behavioral Neuroscience. 2004;118:157–162
  24. Gallinat J, Kunz D, Lang U, Kalus P, Juckel G, Eggers J, et al. Serotonergic effects of smoking are independent from the human serotonin transporter gene promoter polymorphism: evidence from auditory cortical stimulus processing. Pharmacopsychiatry. 2005;38:158–160
  25. Gelernter J, Cubells J, Kidd J, Pakstis A, Kidd K. Population studies of polymorphisms of the serotonin transporter protein gene. American Journal of Medical Genetics. 1999;88:61–66
  26. Gijsman H, Cohen A, Van Gerven J. The application of the principles of clinical drug development to pharmacological challenge tests of the serotonergic system. Journal of Psychopharmacology. 2004;18:7–13
  27. Greenberg B, Tolliver T, Huang S, Li Q, Bengel D, Murphy D. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. American Journal of Medical Genetics. 1999;88:83–87
  28. Hallikainen T, Saito T, Lachman H, Volavka J, Pohjalainen T, Ryynanen O, et al. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior. Molecular Psychiatry. 1999;4:385–388
  29. Handelsman L, Holoway K, Kahn R. Hostility is associated with a low prolactin response to meta-chlorophenylpiperazine in abstinent alcoholics. Alcohol, Clinical and Experimental Research. 1996;5:824–829
  30. Handelsman L, Kahn R, Sturiano C, Rinaldi P, Gabriel S, Schmeidler J, et al. Hostility is associated with a heightened prolactin response to meta-chlorophenylpiperazine in abstinent cocaine addicts. Psychiatry Research. 1998;80:1–12
  31. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry. 1996;66:2621–2624
  32. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biological Psychiatry. 2000;47(7):643–649(Apr)
  33. Hoehe M, Wendel B, Grunewald I, Chiaroni P, Levy N, Morris-Rosendahl D, et al. Serotonin transporter (5-HTT) gene polymorphisms are not associated with susceptibility to mood disorders. American Journal of Medical Genetics. 1998;81:1–3
  34. Hoyer D, Clarke D, Fozard J, Hartig J, Martin G, Mylecherane E, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacological Reviews. 1994;46:157–203
  35. Johnson B. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs. 2004;18:1105–1118
  36. Jönsson E, Nöthen M, Gustavsson J, Neidt H, Bunzel R, Propping P, et al. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Research. 1998;79:1–9
  37. Kahn R, Wetzler S. M-Chloropiperazine as a probe of serotonin function. Biological Psychiatry. 1991;30:1139–1166
  38. Kalus O, Wetzler S, Kahn R, Asnis G, van Praag H. A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects. Psychopharmacology. 1992;106:388–390
  39. Kotler M, Cohen H, Kremer I, Mel H, Horowitz R, Ohel N, et al. No association between the serotonin transporter promoter region (5-HTTLPR) and the dopamine D3 receptor (BalI D3DR) polymorphisms and heroin addiction. Molecular Psychiatry. 1999;4:313–314
  40. Krystal J, Webb E, Cooney N, Kranzler H, Charney D. Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. Archives of General Psychiatry. 1994;51:898–911
  41. Lesch K, Merchdorf U. Impulsivity, aggression and serotonin: a molecular psychobiological perspective. Behavioral Sciences and the Law. 2000;18:581–604
  42. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:527–531
  43. Li T, Liu X, Zhao J, Hu X, Ball D, Loh-el-W. , et al. Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects. American Journal of Medical Genetics. 2002;114:329–335
  44. Little K, Carrol F, Butts J. Striatal [125I] RTI-55 binding sites in cocaine abusing humans. Progress in Neuropsychopharmacology and Biological Psychiatry. 1998;22:455–466(Apr)
  45. Mannelli P, Patkar A, Murray H, Certa K, Peindl K, Mattila-Evenden M, et al. Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals. Addiction Biology. 2005;10:261–268
  46. Manuck S, Flory J, McCaffery J, Matthews K, Mann J, Muldoon M. Aggression, impulsivity, and central nervous system serotonergic responsivity in a nonpatient sample. Neuropsychopharmacology. 1998;19:287–299
  47. Manuck S, Flory J, Muldoon M, Ferrell R. Central nervous system serotonergic responsivity and aggressive disposition in men. Physiology and Behaviour. 2002;77:705–709
  48. Manuck S, Flory J, Ferrell R. Socio-economic status covaries with central nervous system serotonergic responsivity as a function of allelic variation in the serotonin transporter gene-linked polymorphic region. Psychoneuroendocrinology. 2004;29:651–668
  49. Matthews K, Flory J, Muldoon M, Manuck S. Does socioeconomic status relate to central serotonergic responsivity in healthy adults?. Psychosomatic Medicine. 2000;62:231–237
  50. Miller C, Costa M. Characterization of DNA–protein complexes induced in intact cells by the carcinogen chromate. Molecular Carcinogenesis. 1988;2:125–133
  51. Miles LE, Lipschitz DA, Bieber CP, Cook JD. Measurement of serum ferritin by a 2-site immunoradiometric assay. Analytical Biochemistry. 1974;61:209–224
  52. Muller C, Carey R, Huston J. Serotonin as an important mediator of cocaine's behavioral effects. Drugs Today. 2003;39:497–511
  53. Murphy D, Lesch K, Aulakh C, Pigott T. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature and cardiovascular effects in humans. Pharmacological Reviews. 1991;43:47–55
  54. New A, Trestman R, Mitropoulou V, Goodman M, Koenigsberg H, Silverman J, et al. Low prolactin response to fenfluramine in impulsive aggression. Journal of Psychiatric Research. 2004;38:223–230
  55. Patkar A, Hill K, Weinsten S, Schwartzs S. ECT in the presence of brain tumor and increased intracranial pressure: evaluation and reduction of risk. Journal of ECT. 2000;16:189–197
  56. Patkar A, Berrettini W, Hoehe M, Hill K, Gottheil E, Thornton C, et al. No association between polymorphisms in the serotonin transporter gene and susceptibility to cocaine dependence among African-American individuals. Psychiatric Genetics. 2002;12:161–164
  57. Patkar A, Berrettini W, Hoehe M, Thornton C, Gottheil E, Hill K, et al. Serotonin transporter polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals. Psychiatry Research. 2002;110:103–115
  58. Patkar A, Gottheil E, Berrettini W, Hill K, Thornton C, Weinstein S. Relationship between platelet serotonin uptake sites and measures of impulsivity, aggression, and craving among African American cocaine abusers. American Journal of Addiction. 2003;12:432–437
  59. Patkar A, Mannelli P, Certa K, Peindl K, Murray H, Vergare M, et al. Relationship of serum prolactin with severity of drug use and treatment outcome in cocaine dependence. Psychopharmacology. 2004;176:74–81
  60. Patkar A, Murray H, Mannelli P, Gottheil E, Weinsten S, Vergare M. Pre-treatment measures of impulsivity, aggression and sensation seeking are associated with treatment outcome for African-American cocaine-dependent patients. Journal of Addictive Diseases. 2004;23:109–122
  61. Patkar A, Mannelli P, Peindl K, Hill K, Gopalakrishnan R, Berrettini W. Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients. Psychopharmacology. 2006;17:1–10
  62. Reist C, Mazzanti C, Vu R, Tran D, Goldman D. Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine. American Journal of Medical Genetics. 2001;105:363–368
  63. Retz W, Retz-Junginger P, Supprian T, Thome J, Rosler M. Association of serotonin transporter promoter gene polymorphism with violence: relation with personality disorders, impulsivity, and childhood ADHD psychopathology. Behavioral Science and Law. 2004;22:415–425
  64. Sander T, Gscheidel N, Wendel B, Samochoweic J, Smolka M, Rommelspacher H, et al. Human mu-opioid receptor variation and alcohol dependence. Alcohol, Clinical and Experimental Research. 1998;22:2108–2110
  65. Smith G, Lotrich F, Malhotra A, Lee A, Ma Y, Kramer E, et al. Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology. 2004;29:2226–2234
  66. Stein D, Trestman R, Mitropoulou V, Coccaro E, Hollander E, Siever L. Impulsivity and serotonergic function in compulsive personality disorder. Journal of Neuropsychiatry and Clinical Neuroscience. 1996;8:393–398
  67. Strickland P, John S, Payton A, Worthington J, Ollier W, Deakin J. Do genetic polymorphisms of serotonin (5-HT) neurotransmission influence function in humans?. American Journal of Medical Genetics. 2003;120:556–567
  68. van Dyck CH, Malison RT, Staley JK, Jacobsen LK, Seibyl JP, Laruelle M, et al. Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. American Journal of Psychiatry. 2004;161(3):525–531(Mar)
  69. Whale R, Quested D, Laver D, Harrison P, Cowen P. Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology. 2000;150:120–122
  70. Williams R. Lower socioeconomic status and increased mortality: early childhood roots and the potential for successful interventions. Journal of the American Medical Association. 1998;279:1745–1746
  71. Williams R, Marchuk D, Gadde K, Barefoot J, Grichnik K, Helms M, et al. Central nervous system serotonin function and cardiovascular responses to stress. Psychosomatic Medicine. 2001;63:300–305
  72. Williams R, Marchuk D, Gadde K, Barefoot J, Grichnik K, Helms M, et al. Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology. 2003;28:533–541
  73. Yatham N, Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sciences. 1993;53:447–463
  74. Zuckerman M. P-impulsive sensation seeking and its behavioral, psychophysiological and biochemical correlates. Neuropsychobiology. 1993;28:30–36

☆ Work carried out at: Department of Psychiatry and Behavioral Sciences, Duke University, Durham NC; Department of Psychiatry and Human Behavior, Thomas Jefferson University, Philadelphia PA; Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA.

PII: S0165-1781(06)00024-2

doi: 10.1016/j.psychres.2006.01.012

Psychiatry Research
Volume 144, Issue 2 , Pages 99-108 , 15 November 2006

Article Tools

* Image Usage & Resolution